Published in Br J Cancer on November 04, 2008
Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer (2013) 1.49
Combination chemotherapy with paclitaxel, cisplatin and fluorouracil for patients with advanced and metastatic gastric or esophagogastric junction adenocarcinoma: a multicenter prospective study. Chin J Cancer Res (2012) 0.91
Prognostic factors of second and third line chemotherapy using 5-fu with platinum, irinotecan, and taxane for advanced gastric cancer. Cancer Res Treat (2011) 0.90
Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. J Cancer Res Clin Oncol (2010) 0.89
Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer. Gastric Cancer (2011) 0.89
Second-line treatment of metastatic gastric cancer: Current options and future directions. World J Gastroenterol (2015) 0.86
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival. Gastric Cancer (2012) 0.85
Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy. J Cancer Res Clin Oncol (2013) 0.84
Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. Gastric Cancer (2011) 0.84
Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer. Br J Cancer (2013) 0.81
Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy. BMC Cancer (2014) 0.81
Apatinib in Advanced Gastric Cancer: A Doubtful Step Forward. J Clin Oncol (2016) 0.79
Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer. J Cancer Res Clin Oncol (2010) 0.79
Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes. Gastric Cancer (2016) 0.77
Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. J Cancer Res Clin Oncol (2012) 0.76
A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy. Cancer Chemother Pharmacol (2012) 0.76
Advances in the management of gastric cancer. Indian J Surg (2010) 0.76
Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1. Gastroenterol Res Pract (2015) 0.75
Complete response of a metastatic gastroesophageal adenocarcinoma on irinotecan-based chemotherapy in a dialysis patient. Int J Nephrol Renovasc Dis (2010) 0.75
Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma. Cancer Med (2016) 0.75
Clinical outcomes and prognostic factors for gastric cancer patients with bone metastasis. World J Surg Oncol (2017) 0.75
Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. J Gastric Cancer (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med (2008) 12.97
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol (2006) 9.16
Global cancer statistics. CA Cancer J Clin (1999) 8.82
Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol (2006) 7.21
Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer (1993) 4.99
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer (1995) 4.99
Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer (2000) 4.70
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol (1997) 4.69
Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol (2004) 3.16
The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist (2007) 1.89
Ovarian cancer. Crit Rev Oncol Hematol (2006) 1.64
Evolving chemotherapy for advanced gastric cancer. Oncologist (2005) 1.62
Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol (2007) 1.46
CEA as a monitor of gastrointestinal malignancy. Cancer (1975) 1.33
Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis. J Natl Cancer Inst (1990) 1.30
Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol (2004) 1.26
Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer. Gastric Cancer (2000) 1.21
Gastric cancer--new therapeutic options. N Engl J Med (2006) 1.20
Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol) (2005) 1.20
Gastric cancer. Crit Rev Oncol Hematol (2005) 1.16
Chemotherapy for gastric cancer. World J Gastroenterol (2006) 1.13
Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol (2005) 1.04
Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol (2004) 0.97
Prognostic value of combination assays for CEA and CA 19-9 in gastric cancer. Oncology (1995) 0.94
Serum carcinoembryonic antigen as a prognostic factor in resectable gastric cancer. J Am Coll Surg (1998) 0.90
New drugs for treatment of gastric cancer. Ann Oncol (2002) 0.87
Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen). Cancer Invest (2003) 0.87
Improving patient management in metastatic non-small cell lung cancer. Lung Cancer (2007) 0.82
Relationship between peritoneal collagen type IV concentrations and the presence of disseminated metastases in gastric cancer. Arch Surg (1995) 0.81
A new class of membrane-bound chemokine with a CX3C motif. Nature (1997) 7.87
Impact of a patient-centered, computer-based health information/support system. Am J Prev Med (1999) 6.60
Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature (1998) 4.03
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer (2009) 3.73
Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J Endocrinol Invest (2006) 3.17
CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3alpha and is highly expressed in human dendritic cells. J Exp Med (1997) 2.24
Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol (2012) 2.07
Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol (2000) 2.07
Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol (2002) 2.03
Potential utility of early metabolic response by 18F-2-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in a selected group of breast cancer patients receiving preoperative chemotherapy. Eur J Cancer (2013) 2.01
Antigen retrieval techniques in immunohistochemistry: comparison of different methods. J Pathol (1997) 2.01
Use of octogenarian donors for liver transplantation: a survival analysis. Am J Transplant (2014) 2.00
Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol (1997) 1.94
Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J (1999) 1.92
The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J Pathol (2008) 1.83
Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Ann Oncol (2010) 1.81
A dosage sensitive locus at chromosome Xp21 is involved in male to female sex reversal. Nat Genet (1994) 1.78
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol (2012) 1.78
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia (2012) 1.68
Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol (2001) 1.63
Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J (2010) 1.63
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer (2005) 1.61
Bone metastases in breast cancer: higher prevalence of osteosclerotic lesions. Radiol Med (2007) 1.58
Control of the citric acid cycle by glyoxylate. Mechanism of the inhibition by oxalomalate and gamma-hydroxy-alpha-oxoglutarate. Biochem J (1967) 1.58
Central nervous system side effects associated with zolpidem treatment. Clin Neuropharmacol (2000) 1.54
Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: a single-centre comparison amongst four different staging systems. J Intern Med (2004) 1.53
Magnetic resonance imaging of central nervous system lesions in patients with lupus erythematosus. Correlation with clinical remission and antineurofilament and anticardiolipin antibody titers. Arthritis Rheum (1991) 1.53
Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging. Ann Oncol (2004) 1.51
Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer (1998) 1.50
Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. Br J Cancer (2009) 1.48
Outcome of antenatally diagnosed intracranial hemorrhage: case series and review of the literature. Ultrasound Obstet Gynecol (2003) 1.48
Resection-line involvement in gastric cancer patients undergoing curative resections: implications for clinical management. Jpn J Clin Oncol (1999) 1.48
Italian cross-sectional growth charts for height, weight and BMI (6-20 y). Eur J Clin Nutr (2002) 1.46
Onychoblastoma (hamartoma of the nail unit): a new entity? Br J Dermatol (2005) 1.43
Gastrointestinal autonomic nerve tumor of the jejunum. Case report and review of the literature. Ital J Gastroenterol Hepatol (1997) 1.42
Fat depot-related differences in gene expression, adiponectin secretion, and insulin action and signalling in human adipocytes differentiated in vitro from precursor stromal cells. Diabetologia (2007) 1.42
Chlamydia trachomatis infection in children with wheezing simulating asthma. Lancet (1992) 1.42
Whole body hyperthermia induction of soluble tumor necrosis factor receptors: implications for rheumatoid diseases. J Rheumatol (1999) 1.42
Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol (2005) 1.41
Insulin autoantibodies as markers of potential diabetes mellitus. Lancet (1989) 1.40
Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res (2000) 1.40
[Synthesis of 3-hydrazino-pyridazines with basic substituents in 6 positions, with hypotensive activity]. Farmaco Sci (1969) 1.39
Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol (2004) 1.39
Leiomyomatosis in pelvic lymph nodes. Histopathology (1992) 1.39
Fine-needle percutaneous biopsy of renal masses with helical CT guidance. Radiology (2000) 1.38
Comparative evaluation of three human immunodeficiency virus genotyping systems: the HIV-GenotypR method, the HIV PRT GeneChip assay, and the HIV-1 RT line probe assay. J Clin Microbiol (2000) 1.38
Transmission of prions. Proc Natl Acad Sci U S A (2002) 1.36
Anion conductance behavior of the glutamate uptake carrier in salamander retinal glial cells. J Neurosci (1996) 1.34
High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy. Ann Oncol (2009) 1.34
Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest (2000) 1.32
Spatially segregated control of Ca2+ release in developing skeletal muscle of mice. J Physiol (1999) 1.31
Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs (1998) 1.31
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol (2012) 1.28
Expression of the ryanodine receptor type 3 calcium release channel during development and differentiation of mammalian skeletal muscle cells. J Biol Chem (1997) 1.27
Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene. Diabetologia (2006) 1.26
Hepatocyte growth factor and macrophage inflammatory protein 1 beta: structurally distinct cytokines that induce rapid cytoskeletal changes and subset-preferential migration in T cells. Proc Natl Acad Sci U S A (1994) 1.25
Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol (1994) 1.23
2,6-Dialkylpiperazines. V. Synthesis of 2,6-alkylpiperazine derivatives structurally related to cinnarazine. J Med Chem (1968) 1.23
Peroxynitrite inhibits glutamate transporter subtypes. J Biol Chem (1996) 1.21
In situ activation of the type 2 ryanodine receptor in pancreatic beta cells requires cAMP-dependent phosphorylation. Proc Natl Acad Sci U S A (1998) 1.21
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J (2007) 1.20
Dyskerin expression influences the level of ribosomal RNA pseudo-uridylation and telomerase RNA component in human breast cancer. J Pathol (2006) 1.20
Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol (1995) 1.18